The past 10years have seen remarkable progress in the global scale-up of human papillomavirus(HPV)vaccinations.Forty-threelow-andlower-middle-incomecountries(LLMICs)havegainedexperienceindeliveringthisvaccinetoyoungadolescent girlsthroughpilotprograms,demonstrationprograms,andnationalintroductionsand mostofthesehaveoccurredinthelast4years.TheexperienceofSenegalissummarizedasanillustrativecountrycasestudy.Publicationofnumerousdeliveryexperi-encesandlessonslearnedhasdemonstratedtheacceptabilityandfeasibilityofHPV vaccinationsinLLMICs.Fourareasrequirededicatedactiontoovercomeremaining challengestonationalscaling-up:maintainingmomentumpolitically,planningsuccessfully,securingfinancing,andfosteringsustainability.Advancesinpolicy,programming, andsciencemayhelpacceleratereaching30milliongirlsinLLMICswithHPVvaccine by 2020. K E Y W O R D S
| INTRODUCTION
Human papillomavirus (HPV) vaccines have been available since 2006.Numerousclinicaltrialsofquadrivalent(HPVtypes6, 11, 16, 18) and bivalent (HPV types 16, 18) HPV vaccines demonstrated nearly 100% prophylactic efficacy against vaccine type persistent infections and cervical intraepithelial neoplasia (CIN), the necessaryprecursorstocervicalcancer, 1-3 leadingtoapprovalandcommercial availability.Thesevaccines have proven tobelong-lasting against both infection and disease clinical endpoints, 4,5 eliciting veryhighantibodylevelsandaviditysuggestiveofenduringprotection. [6] [7] [8] LongitudinalstudiesofthebivalentHPVvaccinesuggestit confershighlevelsofcross-protectionagainstHPVtypesnottargeted by the vaccine. 9 In addition to primary safety assessments conductedasapartoftheoriginalefficacytrials, 10 expertagencies have maintained vigilant post-licensure monitoring of the safety of HPV vaccines, with recent reviews conducted in 2015 by the EuropeanMedicinesAgencyandbytheGlobalAdvisoryCommittee onVaccineSafetyoftheWHO,confirmingthecontinuedsafetyof theiruse. 11, 12 Since April 2009, the WHO has recommended that HPV vaccination be included in national immunization programs, provided that in each country preventing cervical cancer constitutes a public health priority, introduction is programmatically feasible, sustainable financingcanbesecured,andthecost-effectivenessofHPVvaccinationstrategiesareconsidered. 13 
In2014theWHOStrategicAdvisory
Group of Experts on immunization reviewed new research and rec-ommendedrevisionstotheWHOpositionpapertoreducethepreviouslyrequiredthree-dosescheduletoatwo-doseschedule(0and 6-15months afterwards for the second dose) for HPV vaccination forgirlsaged9-14years, 14 8, 15 Since2013,Gavi,theVaccineAlliance(Gavi),hasmadeHPVvaccinesavailabletoeligiblecountriesatsubsidizedpricesrangingfrom US$0.20perdoseto20%oftheGavipurchaseprice(currentlyaround $4.50perdose), 16 dependinguponincomelevel.Alllow-incomecountries(n=31)andnearlyhalfoflower-middleincomecountries(n=23) are currently eligible to access vaccines at these discounted prices through Gavi. Countries can apply for national introduction of HPV vaccine through Gavi, to receive subsidized vaccine and a one-time vaccineintroductiongrantat$2.40pereligiblegirlaspartialsupport for start-up expenses for national rollout. 16 Table S1 ). We review their progress with HPV vaccine introduction, remainingchallenges,andactionsneededtoachievetheGavigoalfor 2020.TheexperienceofSenegalissummarizedasanillustrativecountrycasestudy.
| PROGRESS TO DATE IN LLMICS
InitialnationalintroductionsofHPVvaccineoccurredinhigh-income countriesandfocusedonadolescentgirlsaged12-14yearsthrough school-based programs. 19, 20 Some early adopter countries implementedtime-limitedcatch-upcampaignsforyoungwomenuptoage 18years or older. National introductions of HPV vaccine expanded in high-resource countries from 2008-2012, with a few countries, such as Denmark, opting for clinic-based delivery. 20 Most countries providethevaccinefree-of-chargeorfullyreimbursablethroughtheir national immunization programs. In early reports, population-based three-dosecoverageinthesecountrieshasrangedfrom32%(USA)to 98%(Malaysia),withmost(29of54countriesreportingrecentdata) averagingover70%coverageinthetargetpopulation. 20
| Early pilots and national introductions
Atthetimeoftheinitialintroductionsinhigh-incomecountries,there wasuncertaintyastowhetherandhowHPVvaccinescouldbedelivered in low-resource settings. 21, 22 To study these questions, PATH partnered with ministries of health in four low-and middle-income countries-India,Peru,Uganda,andVietnam-tocarryoutdemonstrationprograms. 23 Conductedfrom2007-2010andreachingfrom4000 to25000youngadolescentgirls,theseprogramsresultedin56%-99% three-dosevaccinecoverage,illustratedtheacceptabilityandfeasibilityofsuchprograms,estimatedthecostsofHPVvaccinedeliveryin low-resourcesettings, [23] [24] [25] [26] [27] [28] [29] [30] [31] andprovidedaguidefortheimplementation of such programs in other countries. 32 In addition, Merck & Co establishedtheGardasilAccessProgram(GAP)in2009. 33 Initialpilot programsin2009and2010wereconductedbycivilsocietyorganizations,universities,nongovernmentalorganizations,andafewgovern-mentsin10countries. 34 Boththeapproachesandeligiblepopulations variedwidely.Bytheendof2014,all31oftheGAPpilotprogramshad been completed in 21 LLMICs, with the majority reporting that they reachedmorethan70%oftheirHPVvaccineuptakegoal. 33, 35 Two countries-Bhutan and Rwanda-introduced HPV vaccine nationally with donations from Merck & Co. In 2010, Bhutan rolled out a school-based national program for all girls aged 12years, plus catch-up vaccinations for the 13-18-year-old female population. 36 Coverage in the firstyearwas 99% among 12-year-olds and 89% in thecatch-uppopulation.Thecountryswitchedtoroutinedeliveryin health facilities from 2011-2013 for several reasons, including concerns about sustaining financing for delivery, and during this period coveragerangedfrom67to69%. 36 
| Expanding access
Access to HPV vaccination in LLMICs has been facilitated by financial assistance, scientific advances, and program tools. In late 2012, assistanceforLLMICsincreasedwiththeannouncementbyGaviofa purchasepriceof$4.50-$4.60perdoseofHPVvaccinefromMerck & Co or GlaxoSmithKline. 16 Since 2013, most financial support for LLMICstointroduceHPVvaccineshasbeenthroughGavi,whichhas approved support for21demonstration programsandfournational programs. 18, 38 In2016Gavimadeaone-timeofferofcatalyticsupport to13countries(ofwhichsevenhavebeenapproved)that"graduated" from eligibility for Gavi support prior to 2013. By and large, countriesaretargetingvaccinationstoayoungerage,frequentlyaged9or 10years,andchoosingtouseprimaryschoolsasalocationforvaccination given that the largest proportion of the eligible population is attending school. [39] [40] [41] [42] These programs have been able to achieve levelsofvaccinecoveragecomparablewiththoseobservedinhighincomecountries-predominantly70%orgreater. 18, 39 Accessalsohasbeenexpandedbyevidencefortheefficacyand effectivenessofHPVvaccinesgivenonthetwo-doseschedule,with countriesswitchingtheirGaviprogramstothenewlyrecommended schedule.Withonelesscontactbetweenvaccinatorsandthetarget population, cost declined and feasibility of delivery increased. 39 The revised recommendation also opened up new delivery options for dosespacing-upto15monthsbetweenfirstandseconddose-allowingforannualschedules,asinChile. 14, 43 Severalcountriesthathave completedtheir2-yearGaviHPVdemonstrationprogramshaveindicatedthattheyareconsideringimplementationofanannualschedule (0and12months)astheirnationalintroductionstrategy(VivienTsu, personalwrittencommunication,December2016). 44 InadditiontothefinancialandvaccinesupportprovidedtoLLMICs through Gavi, tools and resources for planning and implementing effectiveHPVvaccinedeliveryprogramsareavailableinmultiplelanguages. 32, [45] [46] [47] [48] [49] [50] TheLondonSchoolofHygieneandTropicalMedicine andPATHconductedarecentcomprehensivereviewofexperiencesin HPVvaccinedeliveryinmorethan40low-andmiddle-incomecountries and generated materials in multiple languages for countries to learn about the global experience to date. 39, 50 Gavi also supports a varietyofpartnerstoprovidecountrieswithtechnicalassistancefor theplanning,implementation,andevaluationofHPVvaccinedelivery. 
| Country example: Senegal

| Summary
Inthepast10years,wehaveseenremarkableprogressintheglobal scale-up of HPV vaccinations: more than 100 countries now have experiencewithHPV-vaccinedelivery( Fig.1A-D International advocacy groups can also play an important role in keeping momentum. Several agencies and initiatives provide timely informationontheglobalburdenofdiseaseandthedisproportionate impact cervical cancer has in LLMICs. 53, 54 The First Ladies Initiative andtheCervicalCancerPreventionInitiativeareexamplesofforums that are used to build political engagement and commitment from countrydecisionmakers. 55, 56 Momentum for action also can be supported by new scientific evidence.Theevidenceisbecomingmorerobustforthetremendous impact that HPV vaccines are having on infection and disease outcomes.Todate,morethan40studiesofincident,persistentorprevalent infections, genital warts, and CIN across many countries have demonstrated significant reductions in vaccinated populations. [57] [58] [59] [60] [61] Furtherevidenceofherdprotectioninunvaccinatedpopulationsdue toprotectionprovidedbyHPVvaccineprograms, 57,61 eveninplaces with low coverage, 57,59 is particularly encouraging for stakeholders who worry that high coverage is too difficult to achieve. These advancesneedtobebroughttotheattentionofdecisionmakersand partners to maintain political will and momentum for HPV vaccine introduction.
| REMAINING CHALLENGES
| Maintaining momentum
| Planning successfully
Aconsistentlearningfromthepast10yearsofHPVvaccinedeliveryin
LLMICsisthatpoorplanningnegativelyimpactsprograms.Examples of poor groundwork include not coordinating with the education sector for school-based vaccinations [39] [40] [41] ; not allowing sufficient time for the planning process itself; and not adequately sensitizing nationallevelstakeholders,communityleaders,andparentsofeligible girls. 39, 62 Confusionintheeligibilitycriteriaandapplicationofthose criteriaduringvaccinationswasalsonotedasachallenge. 39 Guidance from WHO suggests countries need to consider 6-9months as the minimaltimetoplanaqualityHPVvaccinationprogram. 45 
| Securing financing
Despitenumerousstudiesofthecost-effectivenessofHPVvaccine introduction inLLMICs, [63] [64] [65] therearefew published dataondocumentedcostsofdeliveryandthecomponentsofthosecosts. 31, [66] [67] [68] Microcosting studies done with the early demonstration programs andGAPpilotprogramsestimatedthattheincrementalfinancialcosts forHPVvaccinedeliveryrangedfrom$1.11to$2.74perdose(based onthethree-dosescheduleimplementedatthetime). 31, 69 However, costinganalysesfromfiveinitialGaviHPVdemonstrationprograms resultedinestimatedfinancialcostsofdeliverybetween$3.10and $9.21 per dose (three-dose schedule). 39 For comparison, the two LLMIC national programs that conducted detailed costing analyses aftervaccinationsdeterminedthatitcost$2.40perdosedeliveredin
Bhutan'sschool-basedprogramin2010and$3.37perdosedelivered inRwanda'sinitialschool-basedprogramfrom2011. 36, 70 The cost per dose in HPV demonstration programs masks two important dynamics-first, the proportion attributable to startup expensesversusthatforrecurrentcosts;andsecond,thecomponents startupanddeliverycosts;andsecuringadequatebudgetfromgovernmentand/ordonors. 39 Programs that leverage existing structures, processes, and activities conducted routinely by national immunization programswill be more likely to gain cost efficiencies for HPV vaccine introduction. 
| Fostering sustainability
| GOAL FOR 2020: REACHING 30 MILLION GIRLS
A global analysis of HPV vaccination coverage suggested that only 1%ofyoungwomenaged10-20yearsinLLMICshadbeenfullyvaccinated by the end of 2014. 73 Renewedcommitment,collaboration,andcoordinationbyallpart-nerscanmakethegoalofreaching30milliongirlsinLLMICswithHPV vaccine by 2020 a reality. We know what it takes. Now, more than ever,isthetimetomovefromknowledgetoaction.
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Table S1. HPV vaccination experience in low-and lower-middleincomecountries,asofDecember2016.
